Utah Medical Products (UTMD) EBITDA Margin (2010 - 2026)

Utah Medical Products' EBITDA Margin history runs 17 years deep, the most recent figure standing at 29.41% for Q1 2026.

• On a quarterly basis, EBITDA Margin fell 306.0% year-over-year to 29.41% in Q1 2026; TTM through Mar 2026 was 28.81%, a 395.0% decrease from a year earlier, with the FY2025 full-year figure at 29.6%, down 363.0% from the prior year.
• EBITDA Margin advanced to 29.41% in Q1 2026 per UTMD's latest filing, from 26.99% in the prior quarter.
• Across five years, EBITDA Margin topped out at 39.68% in Q3 2022 and bottomed at 26.61% in Q3 2025.
• The 5-year median for EBITDA Margin is 33.06% (2024), against an average of 33.25%.
• Across the five-year window, EBITDA Margin slumped 794 bps in 2023 and jumped 167 bps in 2024, its largest moves.
• Year by year, EBITDA Margin stood at 37.35% in 2022, then declined by 14 bps to 31.98% in 2023, then grew by 0 bps to 32.0% in 2024, then dropped by 16 bps to 26.99% in 2025, then grew by 9 bps to 29.41% in 2026.
• Per Business Quant, the three latest UTMD EBITDA Margin figures stand at 29.41% (Q1 2026), 26.99% (Q4 2025), and 26.61% (Q3 2025).